News
IVF provider launches its first clinics in Southeast Asia
Demand for IVF and related fertility services is rapidly growing in Southeast Asia
The IVF provider Generation Prime has announced the launch of its first clinics in Bangkok and Kuala Lumpur, as the Asia-Pacific IVF market is expected to reach US$46b by 2031.
The clinics are the first in a series of 15 roll-ups across Thailand, Malaysia, and Singapore, providing access to fertility services for Southeast Asia’s 600 million residents.
Investment in Generation Prime was led by Recharge Capital, with additional investment from Thiel Capital, and Shamrock Holdings, Inc, an investment vehicle for the Disney Family, Blue Lion Global.
Junyi Hou, head of investment operations at Generation Prime, said: “We are thrilled to open our first health services clinics serving individuals across Southeast Asia.
“Our state of the art clinics are designed to assist people wherever they are on their fertility journeys, and we look forward to expanding our clinic network in the region.”
According to studies, 50 per cent of couples are expected to rely on IVF for conception by 2045.
Demand for IVF and related fertility services is rapidly growing around the world, particularly in Southeast Asia, which has seen a notable population decline in recent years.
China alone accounts for one million IVF cycles annually, equivalent to ~40 per cent of the global market, and exports an additional ~500,000 cycles each year due to a mix of regulatory and demand constraints.
By traveling to its clinics in Thailand, Malaysia, and Singapore as medical tourists, Generation Prime hopes its patients could receive access to fertility care at a fraction of the cost compared to countries like China.
“Generation Prime is well-positioned to emerge as a leading IVF and fertility service provider in Southeast Asia due to a combination of their brand new facilities, top-notch team, and emphasis on accessibility,” said Lorin Gu, founding partner of Recharge Capital.
“At Recharge Capital, we have identified women’s healthcare as a thematic sector primed for long-term growth, and companies like Generation Prime are leading the way to make key services like IVF more accessible and cost-effective for women around the world.”
Singapore-based Generation Prime offers services, including assisted conception, fertility preservation, advanced fertility tests, third party reproduction, and pre-implantation genetic testing.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






